Search research articles
Contact Us
Filters
Showing results (21-30 of 70) with videos related to
Page
of 7
Sort By:
Melanoma Research
|
December 18, 2018
Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma
Ben Boursi, Thomas J Werner, Saeid Gholami, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2019
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
Geoffrey T Gibney, Omid Hamid, Jose Lutzky, et al.
Oncoimmunology
|
March 1, 2021
A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes
Amit Maity, Rosemarie Mick, Ramesh Rengan, et al.
The Oncologist
|
May 13, 2022
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
Thomas B Karasic, Timothy J Brown, Charles Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2018
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C Mitchell, Omid Hamid, David C Smith, et al.
The Oncologist
|
June 6, 2022
Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
Emily J Anstadt, Brian Chu, Nikhil Yegya-Raman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2024
FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma
Thomas M Anderson, Bryan H Chang, Alexander C Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2024
Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival
Kevin L Ma, Tara C Mitchell, Meaghan Dougher, et al.
Developmental Cell
|
January 27, 2022
ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression
Wei Zhang, Wenqun Zhong, Beike Wang, et al.
Cancer Immunology Research
|
June 11, 2026
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells
Shujing Liu, Alain H Rook, Alexander C Huang, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 70) with videos related to
Sort By:
Page
of 7
Melanoma Research
|
December 18, 2018
Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma
Ben Boursi, Thomas J Werner, Saeid Gholami, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2019
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
Geoffrey T Gibney, Omid Hamid, Jose Lutzky, et al.
Oncoimmunology
|
March 1, 2021
A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes
Amit Maity, Rosemarie Mick, Ramesh Rengan, et al.
The Oncologist
|
May 13, 2022
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
Thomas B Karasic, Timothy J Brown, Charles Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2018
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C Mitchell, Omid Hamid, David C Smith, et al.
The Oncologist
|
June 6, 2022
Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
Emily J Anstadt, Brian Chu, Nikhil Yegya-Raman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2024
FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma
Thomas M Anderson, Bryan H Chang, Alexander C Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2024
Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival
Kevin L Ma, Tara C Mitchell, Meaghan Dougher, et al.
Developmental Cell
|
January 27, 2022
ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression
Wei Zhang, Wenqun Zhong, Beike Wang, et al.
Cancer Immunology Research
|
June 11, 2026
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells
Shujing Liu, Alain H Rook, Alexander C Huang, et al.
Page
of 7